Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Papillary Renal Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03091192
What this trial is testing

Savolitinib vs. Sunitinib in MET-driven PRCC.

Who this might be right for
CarcinomaCarcinoma, Renal CellKidney Neoplasms+5 more
AstraZeneca 60
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Not applicableStudy completedNCT06111560
What this trial is testing

Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Sun Yat-sen University 160
Testing effectiveness (Phase 2)Study completedNCT00060307
What this trial is testing

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Who this might be right for
Recurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05620134
What this trial is testing

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
CancerTumor, SolidAdvanced Solid Tumor+19 more
Salubris Biotherapeutics Inc 263
Early research (Phase 1)Looking for participantsNCT06792552
What this trial is testing

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsPlatinum Resistant Ovarian CancerFallopian Tube Cancer+5 more
NextCure, Inc. 738
Testing effectiveness (Phase 2)Study completedNCT00126503
What this trial is testing

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Who this might be right for
Chromophobe Renal Cell CarcinomaClear Cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma+3 more
National Cancer Institute (NCI) 73
Large-scale testing (Phase 3)Active Not RecruitingNCT05043090
What this trial is testing

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Who this might be right for
Papillary Renal Cell Carcinoma
AstraZeneca 148
Testing effectiveness (Phase 2)Active Not RecruitingNCT04413123
What this trial is testing

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Who this might be right for
Papillary Renal Cell CarcinomaUnclassified Renal Cell CarcinomaTranslocation Renal Cell Carcinoma+5 more
Bradley A. McGregor, MD 60
Testing effectiveness (Phase 2)UnknownNCT03177239
What this trial is testing

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

Who this might be right for
Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 1Papillary Renal Cell Carcinoma Type 2+3 more
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 85
Testing effectiveness (Phase 2)Study completedNCT01130519
What this trial is testing

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Who this might be right for
HLRCCSporadic Papillary Renal Cell Cancer
National Cancer Institute (NCI) 83
Early research (Phase 1)Study completedNCT01672775
What this trial is testing

Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Who this might be right for
Carcinoma, Renal CellRenal Cell Carcinoma of Papillary HistologyRenal Cell Carcinoma With Clear Cell Histology+1 more
Agensys, Inc. 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716917
What this trial is testing

Genitourinary Tumors With Sacituzumab Tirumotecan

Who this might be right for
Papillary Renal CarcinomaVariant Histology Urothelial Carcinoma
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD 100
Testing effectiveness (Phase 2)Looking for participantsNCT05287945
What this trial is testing

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Oncorena AB 75
Testing effectiveness (Phase 2)Study completedNCT00541008
What this trial is testing

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Who this might be right for
Kidney Cancer
UNICANCER 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT03635892
What this trial is testing

Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced or Metastatic Non-clear Cell Renal Cell CarcinomaUnclassified Renal Cell CarcinomaPapillary Renal Cell Carcinoma+4 more
Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT02761057
What this trial is testing

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Who this might be right for
Locally Advanced Papillary Renal Cell CarcinomaMetastatic Papillary Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7+4 more
National Cancer Institute (NCI) 152
Not applicableNo Longer AvailableNCT05941637
What this trial is testing

An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

Who this might be right for
Clear Cell Kidney CancerKidney CancerKidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Lynkcell Europe
Testing effectiveness (Phase 2)Ended earlyNCT00098618
What this trial is testing

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Clear Cell Renal Cell CarcinomaPapillary Renal Cell CarcinomaRecurrent Renal Cell Cancer+2 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT00459875
What this trial is testing

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Who this might be right for
Kidney Cancer
Memorial Sloan Kettering Cancer Center 24
Next Page